A Risk Sciences International news item posted on April 26, 2022 and last updated on September 9, 2025

Following previous work on the potential risk of acute liver failure associated with quinolone antibiotics, RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski evaluated the potential risk of retinal detachment (RD) associated with these medications.

Although no cases of RD were linked to quinolones in clinical trials, some reports of RD were noted in the US FDA Adverse Event Reporting System in conjunction with systemic use of quinolone antibiotics. Analysis of electronic health records from over 500 US healthcare institutions revealed elevated but non-significant risks in African Americans (ciprofloxacin and levofloxacin), those aged 56–70 years old (moxifloxacin), and women (ciprofloxacin).

The authors noted that these suggestions of increased risk observed in some population subgroups warrant further investigation.

Quinolones
Quinolones

Experts related to this news item

Franco Momoli

Vice-President Chemical and Product Safety

Dr. Franco Momoli joined Risk Sciences International (RSI) in 2019 and currently serves as Vice-President, Chemical and Product Safety. In this role, he leads a multidisciplinary team of epidemiologists, risk assessors, toxicologists, and biostatisticians in conducting human health risk assessments...
Read More about Franco Momoli

Donald Mattison (1944-2026)

Chief Medical Officer, Senior Vice-President

In Memoriam: Dr. Donald Mattison (1944-2026) Dr. Donald Mattison passed away at his home in Columbia, South Carolina on Sunday, March 22, with his family present. Don joined Risk Sciences International (RSI) in 2012 as Vice President and Chief Medical...
Read More about Donald Mattison (1944-2026)

Daniel Krewski

Chief Risk Scientist

Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Read More about Daniel Krewski

More RSI News

IAI climate change report

April 12, 2022

The International Aluminium Institute (IAI) recently commissioned Climate Risk Institute (CRI) and Risk Sciences International (RSI) to produce a series of informational tools evaluating and…

Quinolones and risk of acute liver failure

April 12, 2022

Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski,…

RSI launches Global Risk Census

March 1, 2022

Risk Sciences International has launched The Global Risk Census. The goal of the Census is to provide insights into important risks that need to be…

US FDA FAERS and quinolones

June 22, 2021

Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…